Johnson & Johnson Stock-Based Compensation 2010-2025 | JNJ

Johnson & Johnson stock-based compensation for the twelve months ending March 31, 2025 was $3.045B, a 2.9% decline year-over-year.

  • Johnson & Johnson annual stock-based compensation for 2024 was $1.176B, a 1.2% increase from 2023.
  • Johnson & Johnson annual stock-based compensation for 2023 was $1.162B, a 2.11% increase from 2022.
  • Johnson & Johnson annual stock-based compensation for 2022 was $1.138B, a 0.26% increase from 2021.

Johnson & Johnson Stock-Based Compensation 2010-2025 | JNJ

  • Johnson & Johnson annual stock-based compensation for 2024 was $1.176B, a 1.2% increase from 2023.
  • Johnson & Johnson annual stock-based compensation for 2023 was $1.162B, a 2.11% increase from 2022.
  • Johnson & Johnson annual stock-based compensation for 2022 was $1.138B, a 0.26% increase from 2021.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$796.4B
AbbVie (ABBV)$306B
Novo Nordisk (NVO)$260.6B
Roche Holding AG (RHHBY)$248.1B
Novartis AG (NVS)$234.2B
Merck (MRK)$196.7B
Sanofi (SNY)$128.6B
Pfizer (PFE)$125.6B
Bayer (BAYRY)$23.7B
Innoviva (INVA)$1.1B